AI assistant
H. Lundbeck A — AGM Information 2014
Mar 26, 2014
Preview isn't available for this file type.
Download source fileValby, Copenhagen, 2014-03-26 16:41 CET (GLOBE NEWSWIRE) -- Valby, Denmark, 26
March 2014 - H. Lundbeck A/S (Lundbeck) today announced that at the Annual
General Meeting on 26 March 2014 the proposal to prepare the annual report and
hereby also the quarterly reports of the company in English only was approved.
The report by the Board of Directors was adopted and the annual report was
approved.
The General Meeting approved the remuneration for the Board of Directors for
2014.
The General Meeting approved the dividend of DKK 2.77 per share of DKK 5
nominal value proposed by the Board of Directors.
Håkan Björklund, Christian Dyvig, Thorleif Krarup, Melanie G. Lee and Lars
Rasmussen were re-elected, while Terrie Curran was elected to the Board of
Directors. Jes Østergaard did not stand for re-election. Immediately after the
general meeting, the Board of Directors elected Håkan Björklund as Chairman and
Christian Dyvig as Deputy Chairman of the Board of Directors.
After having elected its Chairman and Deputy Chairman, the Board of Directors
appointed members for the Audit Committee, the Remuneration Committee and the
Scientific Committee.
Thorleif Krarup, Håkan Björklund and Lars Rasmussen were elected as members of
the Audit Committee. Håkan Björklund, Lars Rasmussen and Terrie Curran were
elected as members of the Remuneration Committee. Melanie G. Lee and Christian
Dyvig were elected as members of the Scientific Committee.
The Board of Directors of H. Lundbeck A/S will hereafter comprise:
-- Håkan Björklund (Chairman)
-- Christian Dyvig (Deputy Chairman)
-- Thorleif Krarup
-- Melanie G. Lee
-- Lars Rasmussen
-- Terrie Curran
-- Mona Elisabeth Elster (employee representative)
-- Jørn Møller Mayntzhusen (employee representative)
-- Henrik Sindal Jensen (employee representative)
Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the
company's auditor.
The proposal of the Board of Directors to amend the company's "Remuneration
guidelines for the Board of Directors and the Executive Management of H.
Lundbeck A/S" was approved.
The proposal of the Board of Directors to insert an authorisation in the
Articles of Association to increase the share capital by a nominal amount of up
to DKK 40.000.000 with or without pre-emption rights for the existing
shareholders and the proposal to give the Board of Directors authorisation to
let the company acquire own shares were adopted.
The proposals from a shareholder to include additional financial information in
the notice convening the general meeting, to simplify online access to
financial reports and accounting figures and on provision of meals at general
meetings were withdrawn and the proposals were instead put forward as
recommendations to the Board of Directors .
No other business was handled at the Annual General Meeting.
The Board of Directors
Lundbeck contacts
Investors: Media:
Palle Holm Olesen Mads Kronborg
Chief Specialist, Investor Relations Media Relations Manager
[email protected] [email protected]
+45 36 43 24 26 +45 36 43 30 00
Jens Høyer
Specialist, Investor Relations
[email protected]
+45 36 43 33 86
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company
specialized in brain diseases. For more than 50 years, we have been at the
forefront of research within neuroscience. Our development and distribution of
pioneering treatments continues to make a difference to people living with
brain diseases. Our key areas of focus are alcohol dependence, Alzheimer’s
disease, depression/anxiety, epilepsy, Huntington’s disease, Parkinson’s
disease, schizophrenia and stroke.
Our approximately 6,000 employees in 57 countries are engaged in the entire
value chain throughout research, development, production, marketing and sales,
and are committed to improving the quality of life of people living with brain
diseases. Our pipeline consists of several late-stage development programs and
our products are available in more 100 countries. We have research centers in
China, Denmark and the United States, and production facilities in China,
Denmark, France, Italy and Mexico. Lundbeck generated revenue of DKK 15.3
billion in 2013 (EUR 2.0 billion; USD 2.7 billion).